Human neutrophil peptide in lung chronic allograft dysfunction

Cavan Reilly; Tereza Cervenka; Marshall I. Hertz; Trisha Becker; Chris H. Wendt

doi:10.3109/1354750X.2011.623789

Human neutrophil peptide in lung chronic allograft dysfunction

Cavan Reilly, Tereza Cervenka, Marshall I. Hertz, Trisha Becker, Chris H. Wendt

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Context: Our previous case-control study identified human neutrophil peptide (HNP) as a potential biomarker for bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Objective: To prospectively validate HNP as a biomarker for BOS. Materials and methods: HNP was measured by ELISA in bronchoalveolar lavage (BAL) fluid in lung transplant recipients. Results: The first HNP measurement after reaching baseline pulmonary function was predictive of developing BOS ≥2 (p=0.0419). HNP remained elevated in those that developed BOS. The effect of potential confounders did not significantly impact BOS-free survival time. Conclusion: HNP levels are elevated early and persistently in those that develop BOS.

Original language	English (US)
Pages (from-to)	663-669
Number of pages	7
Journal	Biomarkers
Volume	16
Issue number	8
DOIs	https://doi.org/10.3109/1354750X.2011.623789
State	Published - Dec 2011

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health [Grants HL080041, HL07741] Work performed at the University of Minnesota.

Keywords

Biomarkers
Lung transplant
Rejection

Access

10.3109/1354750X.2011.623789

OpenUrl availability

Full text

Cite this

@article{177de765e8da4d9090b8710c67799597,

title = "Human neutrophil peptide in lung chronic allograft dysfunction",

abstract = "Context: Our previous case-control study identified human neutrophil peptide (HNP) as a potential biomarker for bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Objective: To prospectively validate HNP as a biomarker for BOS. Materials and methods: HNP was measured by ELISA in bronchoalveolar lavage (BAL) fluid in lung transplant recipients. Results: The first HNP measurement after reaching baseline pulmonary function was predictive of developing BOS ≥2 (p=0.0419). HNP remained elevated in those that developed BOS. The effect of potential confounders did not significantly impact BOS-free survival time. Conclusion: HNP levels are elevated early and persistently in those that develop BOS.",

keywords = "Biomarkers, Lung transplant, Rejection",

author = "Cavan Reilly and Tereza Cervenka and Hertz, {Marshall I.} and Trisha Becker and Wendt, {Chris H.}",

note = "Funding Information: This work was supported by the National Institutes of Health [Grants HL080041, HL07741] Work performed at the University of Minnesota.",

year = "2011",

month = dec,

doi = "10.3109/1354750X.2011.623789",

language = "English (US)",

volume = "16",

pages = "663--669",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Human neutrophil peptide in lung chronic allograft dysfunction

AU - Reilly, Cavan

AU - Cervenka, Tereza

AU - Hertz, Marshall I.

AU - Becker, Trisha

AU - Wendt, Chris H.

N1 - Funding Information: This work was supported by the National Institutes of Health [Grants HL080041, HL07741] Work performed at the University of Minnesota.

PY - 2011/12

Y1 - 2011/12

N2 - Context: Our previous case-control study identified human neutrophil peptide (HNP) as a potential biomarker for bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Objective: To prospectively validate HNP as a biomarker for BOS. Materials and methods: HNP was measured by ELISA in bronchoalveolar lavage (BAL) fluid in lung transplant recipients. Results: The first HNP measurement after reaching baseline pulmonary function was predictive of developing BOS ≥2 (p=0.0419). HNP remained elevated in those that developed BOS. The effect of potential confounders did not significantly impact BOS-free survival time. Conclusion: HNP levels are elevated early and persistently in those that develop BOS.

AB - Context: Our previous case-control study identified human neutrophil peptide (HNP) as a potential biomarker for bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Objective: To prospectively validate HNP as a biomarker for BOS. Materials and methods: HNP was measured by ELISA in bronchoalveolar lavage (BAL) fluid in lung transplant recipients. Results: The first HNP measurement after reaching baseline pulmonary function was predictive of developing BOS ≥2 (p=0.0419). HNP remained elevated in those that developed BOS. The effect of potential confounders did not significantly impact BOS-free survival time. Conclusion: HNP levels are elevated early and persistently in those that develop BOS.

KW - Biomarkers

KW - Lung transplant

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=81855168371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855168371&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2011.623789

DO - 10.3109/1354750X.2011.623789

M3 - Article

C2 - 21988113

AN - SCOPUS:81855168371

SN - 1354-750X

VL - 16

SP - 663

EP - 669

JO - Biomarkers

JF - Biomarkers

IS - 8

ER -

Human neutrophil peptide in lung chronic allograft dysfunction

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this